The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT04206787
- Locations
- 🇨🇳
West China Hospital, Chengdu, China
🇨🇳Hainan Cancer Hospital, Haikou, China
🇨🇳First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.
- Conditions
- Healthy
- Interventions
- Drug: BI 474121 oral solutionDrug: BI 474121 tabletDrug: Placebo tabletDrug: Placebo solution
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT04194645
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27190
- Registration Number
- NCT04184297
- Locations
- 🇺🇸
HealthCore, Inc., Andover, Massachusetts, United States
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT04180813
- Locations
- 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳Dongying People's Hospital, Dongying, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, China
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
- Conditions
- Non-squamous, Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 462
- Registration Number
- NCT04179890
- Locations
- 🇬🇧
Royal Marsden Hospital, London, United Kingdom
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT04176536
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Long-acting Muscarinic Antagonists (LAMA)Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9284
- Registration Number
- NCT04172701
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 530
- Registration Number
- NCT04157751
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 413
- Registration Number
- NCT04153929
- Locations
- 🇺🇸
Javara Research, Sugar Land, Texas, United States
🇺🇸San Marcus Research Clinic, Inc., Miami, Florida, United States
🇬🇧Burbage Surgery, Burbage, Hinkley, United Kingdom
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04147234
- Locations
- 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇪🇸CIO Clara Campal, Madrid, Spain